ROSEVILLE, Minn., Dec. 8, 2021 /PRNewswire/ -- Calyxt,
Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology
company, today announced the completion of a key milestone in its
lab-scale BioFactory™ manufacturing system. The results identified
through the Company's metabolomics analyses indicate over 15,000
chemical signatures, including both known and
as-yet-uncharacterized molecules and building block precursors,
chemical compounds involved in chemical reactions that produce
other compounds. These chemical signatures form a baseline library
available for Calyxt to produce valuable compounds within its
proprietary plant-based biomanufacturing system.
"With this technical milestone, Calyxt builds on our earlier
proofs of concept and bolsters our commercial discussions,
particularly because the families of chemistries identified in
these results perform important functions as active ingredients in
certain of our target markets, like cosmetics, pharmaceuticals and
nutraceuticals," said Michael A.
Carr, President and Chief Executive Officer at Calyxt. "The
promise of the BioFactory – to enable our customers to more
sustainably access finite botanical ingredients – is one step
closer to being realized through these results."
The metabolomics analyses have identified molecules across a
diverse and valuable group of chemical classes including
terpenoids, flavonoids, phenolics, alkaloids, and sterols, plus
chemical signatures that may represent new, previously
uncharacterized plant-based molecules. In addition, Calyxt has
recently completed gene-expression profiling that has identified
patterns of genes that can be used to engineer precursor molecules
for conversion to an even broader suite of chemistries.
"These impactful results build on our previously reported
successes with two proofs of concept, ovalbumin egg white protein
and the antioxidant betanin. Early research indicated our
multicellular plant cell matrices would be capable of producing a
diverse group of chemistries, and that is supported by the analysis
announced today. This broad set of building blocks provide
important tools as we seek to engineer the new and innovative
chemistries our customers are expected to demand," said
Travis Frey, Ph.D., Chief Technology
Officer at Calyxt. "From here, guided by customers' needs and our
proprietary metabolite engineering capabilities, we anticipate the
optimization of target molecule production and performance at
greater scale."
Calyxt's BioFactory will produce the target products, first at
lab volumes, then at pilot, and ultimately at manufacturing
scale. The Company's pilot BioFactory is currently being
installed at its Roseville,
Minnesota, headquarters and is on track to be operational by
the end of 2021.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based
synthetic biotechnology company. The Company leverages its
proprietary PlantSpring™ technology platform to engineer innovative
materials and products for its customers to help them meet their
sustainability goals. Calyxt's diversified offerings are primarily
delivered through its proprietary BioFactory™ production system.
For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of
Calyxt, Inc. Any other trademarks belong to their respective
owners.
Forward-Looking Statements:
This press release
contains "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. In some cases, you can identify these
statements by forward-looking words such as "anticipates,"
"believes," "continue," "estimates," "expects," "intends," "may,"
"might," "plans," "predicts," "projects," "should," "targets,"
"will," or the negative of these terms and other similar
terminology. Forward-looking statements in this press release
include statements about Calyxt's product pipeline and development;
Calyxt's ability to utilize the BioFactory to engineer precursor
molecules and to convert these to broader chemistries demanded by
potential customers; Calyxt's ability to achieve target molecule
production and performance at greater scale; and the commercial
demand for Calyxt's synthetic biology solutions. These and other
forward-looking statements are predictions and projections about
future events and trends based on Calyxt's current expectations,
objectives, and intentions and are premised on current assumptions.
Calyxt's actual results, level of activity, performance, or
achievements could be materially different than those expressed,
implied, or anticipated by forward-looking statements due to a
variety of factors, including, but not limited to: the impact of
increased competition, including competition from a broader array
of synthetic biology companies; disruptions at Calyxt's key
facilities, including disruptions impacting its BioFactory
production system; changes in customer preferences and market
acceptance of Calyxt's products; competition for customers,
partners, and licensees and the successful execution of development
and licensing agreements; the impact of adverse events during
development, including unsuccessful pilot production of compounds
or generation of inconsistent data; disruptions to supply chains,
including raw material inputs for Calyxt's BioFactory; the impact
of changes or increases in oversight and regulation; disputes or
challenges regarding intellectual property; proliferation and
continuous evolution of new technologies; and other important
factors discussed under the caption entitled "Risk Factors" in
Calyxt's Annual Report on Form 10-K and subsequent filings on Form
10-Q or Form 8-K with the U.S. Securities and Exchange Commission.
Any forward-looking statements made by Calyxt's management are
based only on information currently available to it when, and speak
only as of the date, such statement is made. Calyxt does not assume
any obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
Contacts:
Calyxt Media Contact:
David Rosen/John Garabo/Michael
Barron
Argot Partners
(212) 600-1902
media@calyxt.com
Calyxt Investor Relations Contact:
Sherri Spear/Cameron Willis
Argot Partners
(212) 600-1902
investors@calyxt.com
Calyxt Business Development Contact:
Sarah Reiter
Calyxt, Inc.
(612) 427-7881
contact@calyxt.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calyxt-identifies-more-than-15-000-unique-chemical-signatures-in-lab-scale-biofactory-production-run-301439791.html
SOURCE Calyxt, Inc.